about
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancerNottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 casesThe epidemiology of triple-negative breast cancer, including raceCharacterisation of HER heterodimers in breast cancer using in situ proximity ligation assayRisk factors for triple-negative breast cancer in women under the age of 45 yearsTamoxifen Resistance: Emerging Molecular TargetsBiomarkers in triple negative breast cancer: A reviewTargeted Therapies in Triple-Negative Breast CancerAndrogen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisTargeting triple-negative breast cancer: optimising therapeutic outcomesBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Novel therapeutic strategies for patients with triple-negative breast cancerA perspective on anti-EGFR therapies targeting triple-negative breast cancerGene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB familyNovel genes associated with lymph node metastasis in triple negative breast cancerOpportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyThe differences in ultrasound and clinicopathological features between basal-like and normal-like subtypes of triple negative breast cancer.Ultrasound and clinicopathological characteristics of triple receptor-negative breast cancers.Triple negative breast cancer in Moroccan women: clinicopathological and therapeutic study at the National Institute of Oncology.Contrast-enhanced ultrasound improved performance of breast imaging reporting and data system evaluation of critical breast lesionsIdentification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesionsPrognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancerThe clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancersEfficacy of carboplatin-based preoperative chemotherapy for triple-negative breast cancer. A meta-analysis of randomized controlled trialsTriple negative breast carcinoma is a prognostic factor in Taiwanese women.Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyAn integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.Importance of Breast Cancer Subtype in the Development of Androgen Receptor Directed Therapy.Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cellsImmunoexpression of lactoferrin in triple-negative breast cancer patients: A proposal to select a less aggressive subgroup.The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based studyTriple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survivalFavorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotypeClinicopathological features and prognosis of triple negative breast cancer in Kuwait: A comparative/perspective analysis.
P2860
Q21132473-9A95DA2C-6140-49CC-8612-B2602B216C4DQ21261291-7760F8B2-8988-4724-895E-3C2280C78DAEQ21999477-87ABE21B-E560-43CD-A38B-E718C2C72FF4Q24289471-E1838251-23AC-42C0-AD7E-7180E5F1B84DQ24337937-5CF0EC6D-0725-4B2A-9379-143A0D6DFF93Q24644075-27DC221A-F645-4529-BE25-A3E242A6F5D7Q26739969-E0CAD0FE-EFC9-4631-80CC-68455C8ADE28Q26775094-D785CBB5-E3EF-42CC-85ED-5329B9E9BC9AQ26777736-3E42C538-6048-4739-9036-BA39BCEDA21CQ26823419-FBE1224E-BD2F-41AC-880B-052E8D21EC9DQ26850892-FEDB9B88-ECBA-4506-9360-2D6A9E7FC578Q27311085-1C1AAA08-41B1-42EC-A176-87F3A7CF50BDQ28067436-D06A0E86-0F9C-4C73-A8FC-2D29F376048BQ28069867-58CE95C2-8410-4838-8F19-69BD1788E973Q28258227-6A11ACD4-B965-4F7D-A0BB-70BD683AA292Q28393204-ABA33C80-FDB7-4765-8F50-5D777509BF96Q29248325-8F194161-6D97-4E1C-90CB-8062415FB74FQ30417120-18774CDD-09C2-4E74-BC78-FB555F7E435AQ30474511-8C88C9A2-8416-4779-AA70-8F42043194FEQ31102636-6706261E-52A7-42F9-ACA3-8B9F76F6646EQ31111425-E3FB6AA0-1F78-4903-89A7-FAEEB4C507B2Q31134060-476E45DB-B3EF-4B6E-AC90-03279F28AF1EQ31157579-1CBE7D51-9334-48B7-BE82-205B388D7A35Q33304691-55719B06-6CBA-4D9C-BAB8-2F84E2C2E09BQ33378965-294C8DC2-632E-445A-A257-D9C0CD720DE9Q33379276-DB176AA5-2CCD-41DD-BE1D-39A69FB04444Q33438050-7E639B26-35C1-4102-B722-F23129393143Q33470042-E86688B9-8684-49FC-8F08-E72DD7C1A118Q33570282-07FF201D-96CF-4903-A5CA-E75A35252903Q33573055-945C3774-8915-4972-9F15-62B553D34962Q33579640-48B0BE4C-EEC3-4450-A599-6E921757DC14Q33591757-BDCD7FB8-B62A-490A-ADF8-0C60D8875CCEQ33609985-C6BF0C41-039F-4863-B866-C37F71909FECQ33632582-F2FEE22B-A2C6-487C-97FC-61BA82CDF2EAQ33637896-5A6ED3B0-63EE-4B24-9436-2ADFAFA75640Q33684982-A07E0754-AB68-45A7-A8D1-AA2A083F90F9Q33688668-1BEA7724-378D-40B0-BA29-3F8F4299F9A4Q33699438-1F15A087-BA2D-49DF-97F9-CCCB6F039163Q33710233-0C279AB6-22C6-4F7B-86D6-A8DF861EC9ADQ33751806-660D5542-264D-4E41-B66F-DD948E8C58E0
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Prognostic markers in triple-negative breast cancer.
@en
Prognostic markers in triple-negative breast cancer.
@nl
type
label
Prognostic markers in triple-negative breast cancer.
@en
Prognostic markers in triple-negative breast cancer.
@nl
prefLabel
Prognostic markers in triple-negative breast cancer.
@en
Prognostic markers in triple-negative breast cancer.
@nl
P2093
P50
P356
P1433
P1476
Prognostic markers in triple-negative breast cancer.
@en
P2093
Andrew H S Lee
John F Robertson
Maysa E El-Sayed
P356
10.1002/CNCR.22381
P407
P577
2007-01-01T00:00:00Z